F. Di Nicolantonio

@fdinicolantonio

Federica Di Nicolantonio, Associate Professor at University of Torino, Dept of Oncology. Group Leader at Candiolo Cancer Institute, Italy. Tweets are my own.

Vrijeme pridruživanja: veljača 2013.

Tweetovi

Blokirali ste korisnika/cu @fdinicolantonio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @fdinicolantonio

  1. Prikvačeni tweet

    Cancer cells modulate DNA repair in response to therapy. This improves their odds of developing a mutation that will confer drug resistance and allow them to survive.

    Poništi
  2. proslijedio/la je Tweet
    24. sij
    Poništi
  3. proslijedio/la je Tweet
    20. sij

    : We are delighted to offer participants free childcare onsite at EACR 2020, supplied by Nipperbout Event Childcare. Places are limited and must be pre-booked, so register your interest now! To find out more, please visit:

    Poništi
  4. proslijedio/la je Tweet
    14. sij

    Our paper is out today! Crizotinib is the first MET inhibitor to prospectively show activity in METex14-altered NSCLC, is widely available, and is in the NCCN guidelines for this indication. A great treatment option while we wait for the potential approval of a selective MET TKI.

    Poništi
  5. proslijedio/la je Tweet
    15. sij

    Can we challenge the long held hypothesis that resistance to targeted therapy in cancer is present at the time of therapy start? Can we leverage liquid biopsy to monitor? Fantastic talk by

    Poništi
  6. proslijedio/la je Tweet
    12. sij

    A machine learning algorithm uses circulating tumor DNA methylation markers for the diagnosis, prognostication, and surveillance of cancer

    Poništi
  7. proslijedio/la je Tweet
    13. sij

    🔴 WE HAVE SOMETHING TO CELEBRATE: OUR FIRST FULL ISSUE IS LIVE ‼️ - GIVE US BIGGER CAPS TO SHOW OUR EXCITEMENT!! 🥳 🥳 Massive congrats to the team, and thanks to everyone that made this a reality. Stay tuned for our content:

    , , i još njih 6
    Prikaži ovu nit
    Poništi
  8. proslijedio/la je Tweet
    13. sij

    The first issue of is out today. Proud that our lab has contributed one paper in it

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    11. sij

    Holy smokes, this is a cool paper on intratumoral injection of & . Work of Drs. Jenna Newman, Andrew Zloza et al . First few pgs 👇. Full paper & datasets at link w/ no paywall.

    Poništi
  10. proslijedio/la je Tweet
    6. pro 2019.

    Last year, we invited to our animal research facility to find out more about the role of mice in cancer research. And this week the broadcast won an openness award! 🏆 🎧 Listen to the programme ➡️

    Poništi
  11. proslijedio/la je Tweet

    Principal methods for measuring chromatin accessibility: -seq -seq -seq -seq Figure from our Review: Chromatin accessibility and the regulatory epigenome by et al.

    Poništi
  12. proslijedio/la je Tweet

    Lack of detectable neoantigen depletion signals in the untreated cancer genome (Van den Eynden et al.)

    Poništi
  13. proslijedio/la je Tweet
    25. stu 2019.

    What's new and exciting in the field? Read the EACR’s latest Top 10 Cancer Research Publications on magazine:

    Poništi
  14. proslijedio/la je Tweet
    26. stu 2019.

    New work from Reis-Filho and ⁦⁩ in ⁦⁩ reporting a comprehensive analysis revealing as major source of somatic mutations in plasma. ⁦

    Poništi
  15. Congrats for this paper on the footprints of therapies. for 21 wks causes 20 coding-affecting mutations in tumors, while aging induces only 1 mutation

    Poništi
  16. proslijedio/la je Tweet
    18. stu 2019.

    🔴Our first paper just published ! Nabel &co report trispecific antibodies that engage multiple targets & induce enhanced tumor-cell killing. Links here: Free Access Paper: N&Vs : Enjoy! Stay tuned for more!!

    , , i još njih 3
    Poništi
  17. Congrats and INT team for their trial just published in Capecitabine and versus FOLFIRI in mutated, MGMT methylated metastatic cancer. Decreased toxicity seen with capecitabine and temozolomide.

    Poništi
  18. proslijedio/la je Tweet

    This academic trial in colorectal cancer investigated an old drug, temozolomide, for which big pharmas do not longer invest. It was hard to run it!

    Prikaži ovu nit
    Poništi
  19. Thanks to for the highlight of our recent paper on Adaptive Mutability and Resistance to Therapies in

    Poništi
  20. proslijedio/la je Tweet

    Our DNA repair/QC machinery is permissive, for good reasons, as put forth by & Benjamin Hall explaining the high N of passenger mutations (1000 to 10,000 per genome) in normal cells

    Poništi
  21. proslijedio/la je Tweet
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·